Industry news that matters to you.  Learn more

Clinical Advantages of Critical Diagnostics’ Cardiac Biomarker ST2 Featured In YouTube Video

Critical Diagnostics, makers of the Presage® ST2 Assay, recently announced that a six-minute videotape by Antoni Bayes-Genis, MD PhD., head of Cardiology Service at Hospital Germans Trias i Pujol, in Barcelona Spain discussing results of a study just completed on the use of biomarkers over conventional clinical assessments for risk stratification of heart failure patients has been posted on YouTube for immediate viewing.

The study followed 876 heart failure patients with a mean age of 70.3 years for a period of 40 months. During this follow up period, 311 patients died. Researchers compared 11 clinical variables, including age, sex, ischemic etiology of heart failure, left ventricular ejection fraction, New York Heart Association functional class, diabetes, renal function, beta blocker treatment, ace inhibitor treatment, sodium and hemoglobin biomarkers, which are routinely used to stratify heart failure risk against three biomarkers: NT-proBNP from Roche (OTC: RHHBY), high-sensitivity troponin T and Critical Diagnostics’ ST2.

The results from this recent study highlights the enduring clinical utility of ST2 despite being combined with the established and widely accepted cardiac biomarkers, like NTpro BNP, in medical practice. “The best results were obtained for ST2 and high-sensitivity troponin T,” notes Dr. Bayes-Genis, the primary investigator of the study. “Whenever we added NT-proBNP to these other two biomarkers, net reclassification improvement was reduced.”

Check out the video below.

“We are seeing strong adoption of ST2 by leading cardiologists who understand many of the limitations of utilizing natriuretic peptide markers like BNP and NT-proBNP in their practice,” states David Geliebter, CEO of Critical Diagnostics. “Natriuretic peptide markers certainly have their role in diagnosing heart failure, but fall short in guiding treatment of diseased patients. In study after study, ST2 has consistently demonstrated improved accuracy of patient prognosis over natriuretic peptide markers alone.

“Two of the biggest criticisms we hear about natriuretic peptide markers are that their levels don’t change or change too slowly, so their value as a serial marker for guiding treatment is questionable and, furthermore, that results are often skewed by other influencers such as age, gender, body mass index, atrial fibrillation, history of heart failure, anemia and impaired renal failure. By comparison, ST2 levels change rapidly in response to changes in the patient’s condition—sometimes within hours—thus helping physicians make informed decisions on an appropriate course of action to take and, if needed, to quickly adjust care, such as titrating medication. Moreover, unlike natriuretic peptide markers, ST2 levels are not adversely affected by the above-mentioned confounding factors.”

“Heart failure has become a growing public epidemic, with increasing incidence and prevalence,” Dr. Bayes-Genis stresses. “As a result, there is a need to understand risk factors and risk stratifiers, to better identify the patients that are going to have a better or a worse outcome. We now have a new generation of biomarkers, high-sensitivity troponin T and ST2, which are easily measurable in our routine practice, which provide additional information to stratify the prognosis of patients with heart failure.”

Source: Critical Diagnostics

Critical Diagnostics Unveils its “Power of 2” Brand Campaign

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases, today announced it has launched its first U.S. branding campaign to showcase its cardiac biomarker, the Presage® ST2 Assay—which has been approved by the FDA for use as an aid in assessing the prognosis of patients diagnosed with chronic heart failure.

“We consider what we do partnering with healthcare professionals to offer patients hope for a better life,” notes David Geliebter, Chairman and CEO of Critical Diagnostics. “The ‘Power of 2,’ an obvious reference to the ‘2’ in ST2, denotes that valued relationship.”

Heart failure is a progressive disease in which the ability of the heart to provide needed cardiac output weakens, thus impeding the heart’s ability to pump enough blood to support the body’s metabolic demands. According to the American Heart Association, heart failure affects some 5.8 million Americans with 670,000 new diagnoses each year. The estimated direct and indirect cost of this condition in the US is $39.2 billion.

One of the ways that clinicians are improving the lives of heart failure patients, is through the use of cardiac biomarkers. ST2 has been shown to be prognostically meaningful in patients with chronic heart failure. With more accurate risk assessment physicians may make better treatment decisions resulting in improved patient outcomes and an overall reduction in healthcare expenditures.

Presage ST2 Assay levels are both independent and complimentary of the natriuretic peptide markers and not adversely affected by such confounding factors as age, gender, body mass index, atrial fibrillation, anemia and impaired renal function.

The branding campaign begins today, with a monthly ad that will run in Cardiovascular Business magazine, a leading news, business and technology magazine for cardiovascular medicine which reaches over 25,000 cardiovascular decision-makers. Copies of the first two ads can be found on this link: www.criticaldiagnostics.com/ad.

Source: Business Wire

Plasma von Willebrand Factor a Biomarker for Risk of Adverse Events in Anticoagulated Atrial Fibrillation Patients

In patients with atrial fibrillation (AF) who were anticoagulated, plasma levels of von Willebrand factor (VWF) were found to be an independent risk factor for adverse events, including cardiovascular mortality and major bleeding. The study is published in the April 13th online edition of the Journal of the American College of Cardiology.

Xention to Characterize Biomarkers for AF Consortium

Cambridge-based biopharmaceutical company Xention announced yesterday that it is a partner in the new multidisciplinary atrial fibrillation research consortium, the European Network for Translational Research in Atrial Fibrillation (EUTRAF). The consortium has been awarded a 12 million euro grant to engage in atrial fibrillation (AF) research.